Related Experiment Video
Updated: Jun 12, 2025
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Emerging therapeutic and diagnostic strategies for coronary artery disease: Current trends and future perspectives
Suresh Saravanan1, Natarajan Alangudi Palaniappan2, Anthoniammal Panneerselvam3
1Department of Biotechnology, Dr. M.G.R Educational and Research Institute, Chennai, Tamil Nadu, India.
Insights
Coronary artery disease (CAD) treatments are advancing with nanoparticles for targeted drug delivery. Non-coding RNAs (si-RNA, mi-RNA) and stem cells, encapsulated in nanoparticles, offer new therapeutic options for CAD.
Area of Science:
- Cardiovascular Medicine
- Biotechnology
- Nanomedicine
Background:
- Coronary vascular disease (CVD), including coronary artery disease (CAD), poses a significant global health burden.
- Traditional CAD treatments like CABG and PCI have limitations.
- Advancements in science and technology are driving novel therapeutic approaches for CAD.
Purpose of the Study:
- To explore advanced therapeutic strategies for Coronary Artery Disease (CAD).
- To discuss the role of nanoparticles, non-coding RNAs, and stem cells in CAD treatment.
- To highlight the potential of targeted drug delivery and regenerative medicine in managing CAD.
Main Methods:
- Utilizing nanoparticles as carriers for targeted drug delivery in CAD treatment.
- Employing non-coding RNAs (si-RNA, mi-RNA) as therapeutic agents for gene expression regulation in CAD.
- Investigating the regenerative potential of stem cells to improve blood supply and cardiac function in atherosclerosis-affected areas.
- Encapsulating therapeutic agents like RNA and stem cells within nanoparticles to prevent degradation.
Main Results:
- Nanoparticles offer a promising platform for targeted drug delivery in CAD.
- Non-coding RNAs demonstrate unique characteristics for therapeutic intervention in CAD by regulating gene expression.
- Stem cells enhance blood supply and promote cardiac regeneration, addressing tissue damage caused by atherosclerosis.
- Nanoparticle encapsulation protects RNA and stem cells, improving their efficacy in CAD treatment.
Conclusions:
- Emerging treatments involving nanoparticles, non-coding RNAs, and stem cells represent a significant advancement in managing Coronary Artery Disease.
- These novel approaches offer targeted delivery, gene regulation, and regenerative capabilities, potentially overcoming limitations of traditional CAD therapies.
- Further research into these nanomedicine-based strategies holds promise for improved patient outcomes in CAD treatment.
Abstract:
Coronary vascular disease (CVD) is the general term used to cover conditions like narrowed blood vessels that may cause stroke or heart attack. Coronary artery disease (CAD) is one of the CVD and it is the most severe disease worldwide. The traditional treatment for CAD includes Coronary Artery Bypass Graft Surgery (CABG) and Percutaneous Coronary Intervention (PCI). The evolution of science and technology has led to advancement in the treatment of CAD. Nanoparticles are very suitable for the treatment of CAD by using it as a capsule for targeted drug delivery. Non-coding RNAs like si-RNA and mi-RNA are used as therapeutic agents due to their unique characteristics. In recent years, this si-RNA and miRNA usage in treating diseases has significantly increased. These are used as therapeutic agents for CAD treatment due to their properties like unique mode of action and regulation of gene expression. Another treatment for CAD is stem cells. These are used in CAD treatment because they improve blood supply to the areas where the blood vessels are narrowed down due to atherosclerosis and also, they promote cardiac cell regeneration. These RNA and stem cells are usually encapsulated with nanoparticles to avoid degradation. In this article let us discuss in detail about the treatments of CAD.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:30Current Trends in Nursing II
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...